Trial name or title	Assessment of Efficacy of AZD2281 in Platinum Sensitive Serous Ovarian Cancer
Methods	Phase II Randomised, Double Blind, Multicenter Study
Participants	Women with platinum-sensitive serous ovarian tumours following treatment with two or more platinum-containing regimens
Interventions	Randomisation to AZD2281 or placebo
Outcomes	Primary: Efficacity measured by Progression-free survival (PFS) Secondary: Overall survival (OS) Best overall response (ORR) Duration of response Cancer antigen (CA)-125 response measured every 28 days Radiological tumour assessments will be performed every 12 weeks for 1st 60 weeks and then every 24 weeks Safety assessments every 28 days: adverse events (AEs), physical examination, vital signs including blood pressure (BP), pulse, electrocardiogram (ECG) and laboratory findings including clinical chemistry, haematology and urinalysis.
Starting date	August 2008
Contact information	Information.Center@astrazeneca.com
Notes	http://clinicaltrials.gov/show/NCT00753545